Posted by Michael Wonder on 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
16 April 2021 - Final step in Lilly's planned transition to provide only bamlanivimab and etesevimab together in the U.S.
Eli Lilly has requested the U.S. FDA revoke the emergency use authorisation for bamlanivimab (LY-CoV555) 700 mg alone.
Lilly made this request due to the evolving variant landscape in the U.S. and the full availability of bamlanivimab and etesevimab together. This request is not due to any new safety concern.
